Noah L. Rosenberg Sells 870 Shares of Retrophin Inc (NASDAQ:RTRX) Stock
Retrophin Inc (NASDAQ:RTRX) insider Noah L. Rosenberg sold 870 shares of the company’s stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $20.49, for a total value of $17,826.30. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.
Shares of RTRX stock opened at $20.69 on Friday. The stock’s 50-day simple moving average is $18.92 and its 200-day simple moving average is $16.28. The company has a debt-to-equity ratio of 0.92, a current ratio of 5.97 and a quick ratio of 5.88. Retrophin Inc has a fifty-two week low of $8.98 and a fifty-two week high of $21.92.
Retrophin (NASDAQ:RTRX) last announced its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.70. The business had revenue of $47.77 million for the quarter, compared to analyst estimates of $43.14 million. Retrophin had a negative return on equity of 43.15% and a negative net margin of 57.01%. As a group, equities analysts predict that Retrophin Inc will post -1.56 earnings per share for the current fiscal year.
RTRX has been the subject of a number of analyst reports. BTIG Research initiated coverage on Retrophin in a research note on Tuesday, June 16th. They set a “buy” rating and a $25.00 price objective for the company. ValuEngine cut Retrophin from a “strong-buy” rating to a “buy” rating in a research note on Friday, April 17th. Zacks Investment Research raised Retrophin from a “hold” rating to a “strong-buy” rating and set a $23.00 target price on the stock in a research report on Wednesday, July 15th. Canaccord Genuity reaffirmed a “buy” rating and set a $26.00 target price on shares of Retrophin in a research report on Tuesday, May 19th. Finally, BMO Capital Markets reduced their target price on Retrophin from $34.00 to $31.00 in a research report on Monday, July 13th. One investment analyst has rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $27.00.
Retrophin Company Profile
Retrophin, Inc, a biopharmaceutical company, focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.
Featured Article: Diversification in Investing
Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.